Division of Vector-Borne Diseases, Centers for Diseases Control and Prevention, Fort Collins, Colorado, USA
Clin Microbiol Rev. 2017 Dec 13;31(1). doi: 10.1128/CMR.00104-16. Print 2018 Jan.
Beginning in 2004, chikungunya virus (CHIKV) went from an endemic pathogen limited to Africa and Asia that caused periodic outbreaks to a global pathogen. Given that outbreaks caused by CHIKV have continued and expanded, serious consideration must be given to identifying potential options for vaccines and therapeutics. Currently, there are no licensed products in this realm, and control relies completely on the use of personal protective measures and integrated vector control, which are only minimally effective. Therefore, it is prudent to urgently examine further possibilities for control. Vaccines have been shown to be highly effective against vector-borne diseases. However, as CHIKV is known to rapidly spread and generate high attack rates, therapeutics would also be highly valuable. Several candidates are currently being developed; this review describes the multiple options under consideration for future development and assesses their relative advantages and disadvantages.
从 2004 年开始，基孔肯雅病毒（CHIKV）从一种局限于非洲和亚洲的地方性病原体，发展成为一种全球性病原体，导致周期性暴发。鉴于 CHIKV 引起的暴发仍在继续且不断扩大，必须认真考虑确定疫苗和疗法的潜在选择。目前，这方面没有许可产品，控制完全依赖于使用个人防护措施和综合病媒控制，而这些措施的效果非常有限。因此，迫切需要紧急审查进一步控制的可能性。疫苗对虫媒疾病非常有效。然而，由于 CHIKV 传播迅速，发病率高，因此治疗方法也非常有价值。目前正在开发几种候选药物；本综述描述了正在考虑用于未来开发的多种选择，并评估了它们的相对优势和劣势。
